Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
Total Valuation
Terns Pharmaceuticals has a market cap or net worth of $377.30M. The enterprise value is $224.79M.
Market Cap$377.30M
Enterprise Value$224.79M
Share Statistics
Terns Pharmaceuticals has 87,337,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding87,337,800
Owned by Insiders2.45%
Owned by Institutions46.22%
Financial Efficiency
Terns Pharmaceuticals’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -29.30%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-29.30%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-1.51M
Employee Count59
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Terns Pharmaceuticals is -4.96. Terns Pharmaceuticals’s PEG ratio is 0.39.
PE Ratio-4.96
PS Ratio0.00
PB Ratio1.32
Price to Fair Value1.27
Price to FCF-7.43
Price to Operating Cash Flow-7.47
PEG Ratio0.39
Income Statement
In the last 12 months, Terns Pharmaceuticals had revenue of 0.00 and earned -88.85M in profits. Earnings per share was -1.12.
Revenue0.00
Gross Profit0.00
Operating Income-101.87M
Pretax Income-88.59M
Net Income-88.85M
EBITDA-87.70M
Earnings Per Share (EPS)-1.12
Cash Flow
In the last 12 months, operating cash flow was -71.66M and capital expenditures -13.00K, giving a free cash flow of -71.67M billion.
Operating Cash Flow-71.66M
Free Cash Flow-71.67M
Free Cash Flow per Share-0.82
Dividends & Yields
Terns Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.76
52-Week Price Change-42.63%
50-Day Moving Average3.42
200-Day Moving Average4.94
Relative Strength Index (RSI)65.96
Average Volume (3m)812.18K
Important Dates
Terns Pharmaceuticals upcoming earnings date is Aug 11, 2025, After Close (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Terns Pharmaceuticals as a current ratio of 23.14, with Debt / Equity ratio of 0.44%
Current Ratio23.14
Quick Ratio23.14
Debt to Market Cap<0.01
Net Debt to EBITDA1.83
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Terns Pharmaceuticals has paid 260.00K in taxes.
Income Tax260.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Terns Pharmaceuticals EV to EBITDA ratio is -3.20, with an EV/FCF ratio of -4.00.
EV to Sales0.00
EV to EBITDA-3.20
EV to Free Cash Flow-4.00
EV to Operating Cash Flow-4.00
Balance Sheet
Terns Pharmaceuticals has $334.26M in cash and marketable securities with $1.24M in debt, giving a net cash position of -$333.03M billion.
Cash & Marketable Securities$334.26M
Total Debt$1.24M
Net Cash-$333.03M
Net Cash Per Share-$3.81
Tangible Book Value Per Share$4.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Terns Pharmaceuticals is $15.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.75
Price Target Upside264.58% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast10.98%